Dr. Fong has focused on cancer immunotherapy throughout his career. After completing his oncology fellowship at Stanford, he completed post-doctoral training with Drs. Ed Engleman and Mark Davis focused on tumor immunology. He then began his independent research program at UCSF and have continued to focus on how the immune system interacts with cancer as well as developing tumor immunotherapies in both mouse models and in patients. He described the immunogenicity of prostate acid phosphatase (PAP), which is the target antigen for sipuleucel-T, now an FDA-approved immunotherapy for prostate cancer. He was also involved with the first-in-man clinical trials with ipilimumab, an anti-CTLA4 antibody that is now FDA approved for melanoma. He continues to investigate how immunotherapies such as immune checkpoint inhibitors and cancer vaccines can enhance anti-tumor immunity in patients. He served on multiple NIH study sections and on the NCI Steering Committees for Genitourinary Cancer (GUSC) and Investigational Drugs (IDSC)-Immunotherapy Task Force. He has also served on the program committees for ASCO and AACR and on faculty for the AACR/ASCO Vail Methods in Clinical Research Workshop. He is the site PI at UCSF for the NCI-sponsored Cancer Immunotherapy Trials Network (CITN).